May 28, 2021
10 min watch
Save
VIDEO: COVID-19 experience suggests future of cardiometabolic risk reduction
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video exclusive, Putting It Into Practice columnist Jonathan D. Leffert, MD, talks with Christie Ballantyne, MD, about cardiometabolic risk reduction and collaboration between cardiology and endocrinology.
Advancements over the past 30 years in treating lipids, hypertension and diabetes have been “spectacular,” Ballantyne, who is chief of cardiology and director of the Center for Cardiometabolic Disease Prevention at Baylor College of Medicine said, and the COVID-19 experience suggests future advancements. The pandemic highlighted the dangers of obesity, diabetes and CVD, but also solutions from molecular biology and biotech therapeutics, Ballantyne said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Ballantyne reports he receives consulting fees from Abbott Diagnostic, Althera, Amarin, Amgen, Arrowhead Phamaceital, Astre Zeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma Inc., New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic and Sanofi-Synthelabo; and has research grants with Abbott Diagnostic, ADA, AHA, Akcea, Amgen, Esperion, NIH, Norvartis, Regeneron and Roche Diagnostic. Leffert reports no relevant financial relationships.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.